Soterix Medical Inc. has been awarded a Phase I NIH-STTR grant from the National Institute of Neurological Disorders and Stroke (NINDS) for the development of its High-Definition tDCS platform for the treatment of stroke aphasia. City University of New York is the partnering research institution. Clinical trials will be run at University of South Carolina.

Soterix Medical’s Phase I grant of approximately $540,000 extends over a period of more than a year. The NINDS STTR program may provide up to an additional $3 million of follow-on Phase II funding for additional clinical studies. The focus of the project is to design, prototype, and validate the first individualized electro-therapy system for stroke rehabilitation. Patient-specific dose accounting for stroke anatomy will be delivered to target the peri-lesional areas to improve stroke rehabilitation. The stimulation device and protocols developed in this project are further applicable to motor rehabilitation in stroke and other promising areas of targeted electro-therapy.

“We are extremely pleased to have received this funding from NIH-NINDS. This is an important first step in developing and commercializing our High-Definition tDCS platform” said Abhishek Datta, Ph.D., who is the company PI on the award. Dr. Julius Fridriksson, Ph.D. an internationally renowned stroke-aphasia researcher is the Co-Investigator. He will spearhead the clinical trial, which will be performed by his team at University of South Carolina.

Media Contact
Narges Ghazi
Email: contact@soterixmedical.com